Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.

European journal of medicinal chemistry - 27 Jan 2017

Cheng Wei-Chieh, Wang Jen-Hon, Yun Wen-Yi, Li Huang-Yi, Hu Jia-Ming

Abstract excerpt

The rapid discovery of a pharmacological chaperone toward human α-Gal A for the treatment of Fabry disease is described. Two polyhydroxylated pyrrolidines with the (3R,4S,5R) configuration pattern underwent rapid substituent diversity by conjugating the primary aminomethyl moiety of each with a variety of carboxylic acids to generate two libraries (2 × 60 members). Our bioevaluation results showed one member with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Galactosidase
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Stability

Share to Fabry Disease

Share to Hydroxylation

Share to Pyrrolidines

Share to Small Molecule Libraries

Share to Stereoisomerism

Source

Identifiers

PMID: 27744182
DOI: 10.1016/j.ejmech.2016.10.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.PMID 27744182Read ↗

Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.Semantic proximity Read ↗

Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.Semantic proximity Read ↗

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.Semantic proximity Read ↗

Screening methods for identifying pharmacological chaperones.Semantic proximity Read ↗

Second-Generation Pharmacological Chaperones: Beyond Inhibitors.Semantic proximity Read ↗

Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1.Semantic proximity Read ↗

Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.Semantic proximity Read ↗

Pharmacological chaperone therapy for Fabry disease.Semantic proximity Read ↗

Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.Semantic proximity Read ↗

[Pharmacological Chaperone Therapy for Fabry Disease].Semantic proximity Read ↗

Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.Semantic proximity Read ↗

5-C-Branched Deoxynojirimycin: Strategy for Designing a 1-Deoxynojirimycin-Based Pharmacological Chaperone with a Nanomolar Affinity for Pompe Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.